Get our latest issue now

available for iOS, Android & web

latest issue

Lilly takes back diabetes drug from Transition

Daily News | June 18, 2013

Selina McKee

Lilly takes back diabetes drug from Transition


Eli Lilly has taken back from Transition Therapeutics' an experimental diabetes drug for further development following the completion of proof-of-concept trials.


The drugmakers signed a pact back in 2010 under which Transition snapped up the rights to a series of preclinical compounds from Lilly, including TT-401, a dual agonist of the GLP-1 and glucagon receptors which is being developed for type II diabetes and accompanying obesity.  


Lilly has now exercised its option under the deal to take back all development and commercialisation rights to the drug, which has triggered a milestone payment to Transition of $7 million.


Under the terms of the deal, Transition will contribute $14 million to Lilly in three separate instalments during the planned Phase II clinical study, but it stands to receive around $240 million in additional milestone payments if the product eventually makes it to market.


The Canadian group is also eligible for double-digit royalties on sales of TT-401 products, and a low single digit royalty on related compounds, it said.


Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!